financetom
Business
financetom
/
Business
/
Verint Systems Poised to be 'Early Beneficiary' of AI, Says Oppenheimer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Verint Systems Poised to be 'Early Beneficiary' of AI, Says Oppenheimer
Jun 6, 2024 10:15 AM

12:48 PM EDT, 06/06/2024 (MT Newswires) -- Verint Systems ( VRNT ) is positioned to be an "early beneficiary" of artificial intelligence as its open platform enables AI adoption without the need for major IT upgrades, Oppenheimer said in a note.

Oppenheimer said in a Wednesday note that the overall customer experience market is poised for rapid growth, with the total market size expected to double, which should reduce the impact on companies like Verint ( VRNT ) and balance the extra competition from the tech giants.

"Its portfolio of bots is delivering measurable business outcomes, which is driving larger contracts with longer terms," said the investment firm. Revenue, however, "remains a bit soft" and a more meaningful growth could take about 18 months more, Oppenheimer added.

Verint Systems ( VRNT ) reported fiscal Q1 results ahead of market expectations, with non-GAAP diluted earnings of $0.59 and revenue of $221.3 million. Oppenheimer said it raised its fiscal 2025 revenue estimate for the company to $948.6 million from $938.6 million given its improved outlook and strong momentum.

Oppenheimer reiterated its perform rating on Verint Systems ( VRNT ).

The shares of the company were up 4.6% in recent trading.

Price: 36.30, Change: +1.58, Percent Change: +4.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Sep 21, 2025
Sept 21 (Reuters) - Pfizer ( PFE ) is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera ( MTSR ), the Financial Times reported on Sunday, citing unidentified sources. Reuters could not immediately confirm the report. ...
Hardest-hit Vietnam risks losing $25 billion from US tariffs, UN estimates
Hardest-hit Vietnam risks losing $25 billion from US tariffs, UN estimates
Sep 21, 2025
* Vietnam most exposed to US duties in Southeast Asia, UNDP says * Southeast Asia worst impacted region in Asia, UNDP says * Vietnam's footwear exports fell sharply in August, data show By Francesco Guarascio HANOI, Sept 22 (Reuters) - U.S. tariffs imposed in August risk slashing up to one-fifth of Vietnam's exports to the United States, making it the...
SingTel falls after Optus network failure linked to emergency call disruptions, deaths
SingTel falls after Optus network failure linked to emergency call disruptions, deaths
Sep 21, 2025
(Reuters) -Shares of Singapore Telecommunications slid more than 2% on Monday after a technical failure at its unit Optus, Australia's No. 2 telecom carrier, disrupted emergency call services for 13 hours last week and has since been linked to four deaths. The Singapore-listed stock fell 2.3% to S$4.31, its biggest single-day decline in nearly two months. In a statement on...
BRIEF-Pfizer Closes In On $7.3Bn Takeover Of Anti-Obesity Drugmaker Metsera  - FT
BRIEF-Pfizer Closes In On $7.3Bn Takeover Of Anti-Obesity Drugmaker Metsera - FT
Sep 21, 2025
Sept 21 (Reuters) - Pfizer Inc ( PFE ): * PFIZER CLOSES IN ON $7.3BN TAKEOVER OF ANTI-OBESITY DRUGMAKER METSERA - FT * PFIZER WILL PAY METSERA $47.50 IN CASH A SHARE AND A FURTHER $22.50 IF CERTAIN PERFORMANCE MILESTONES ARE MET - FT Source text: https://tinyurl.com/6ty929xb Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved